eISSN: 2300-6722
ISSN: 1899-1874
Medical Studies/Studia Medyczne
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
2/2020
vol. 36
 
Share:
Share:
abstract:
Review paper

Radical therapy of resectable and borderline resectable pancreatic cancer – present state of knowledge. Do we have sufficient data to use neoadjuvant treatment?

Robert Dziura
1
,
Paweł Macek
2, 3
,
Jolanta Smok-Kalwat
1
,
Stanisław Góźdź
1, 2

  1. Department of Clinical Oncology, Holy Cross Cancer Center, Kielce, Poland
  2. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  3. Department of Epidemiology and Cancer Control, Holy Cross Cancer Centre, Kielce, Poland
Medical Studies/Studia Medyczne 2020; 36 (2): 142–147
Online publish date: 2020/06/30
View full text Get citation
 
PlumX metrics:
The incidence of pancreatic cancer has been increasing in recent years. It is expected to be the second or the third leading cause of cancer deaths in high-income countries in the next decade. Standard therapeutic management for patients with resectable pancreatic cancer is surgical resection followed by adjuvant chemotherapy. The main reason for neoadjuvant therapy is that the prognosis with current strategies is unsatisfactory, and we need new treatments to improve overall survival as well as the quality of life of the patients suffering from pancreatic cancer. The aim of this paper is to provide an overview of the recent data on the subject of neoadjuvant treatment concerning resectable and borderline resectable group of patients.
keywords:

pancreatic cancer, neoadjuvant treatment, chemotherapy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.